Revvity, IncNYSE: RVTY
Health Care · Health Care Equipment
$101.11
+6.01%
Vol: 72K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Barclays downgraded Revvity to Equal Weight from Overweight with PT cut to $95 from $118, while TD Cowen raised PT to $120 amid divestiture and FDA clearance news.Mixed▶
Barclays analyst Luke Sergott downgraded Revvity to Equal Weight from Overweight and slashed his price target to $95 from $118. In contrast, TD Cowen's Dan Brennan raised his price target to $120 from $115 with a Buy rating. The bearish action follows Q1 2026 results showing non-GAAP EPS of $1.06 (beat by $0.02) on revenue of $711.1M that missed estimates. Revvity's full-year 2026 revenue guidance of $2.81-$2.84B came in about 5% below consensus, with pro forma organic growth of 3-4% and adjusted EPS of $5.20-$5.30, excluding the planned divestiture of its China Immunodiagnostics unit. The Immunodiagnostic Systems unit secured FDA clearance for a Total Testosterone automated chemiluminescence immunoassay.
May 20Revvity faces analyst price-target cuts amid Q1 sales miss and China divestiture plans.Mixed▶
Revvity reported Q1 2026 revenue of $686.9 million, up 9.3% YoY but short of the $705.1 million consensus, while non-GAAP EPS of $1.06 beat by 4.5%. The company announced plans to divest its China immunodiagnostics business (about 6% of 2025 revenue), with closure anticipated by end of 2027. Revvity received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay, complementing its existing FDA-cleared testosterone-related tests. The company also launched Xynthetica (AI-as-a-service), Signals BioDesign, and the Opera Phenix OptIQ high-content screening system. Multiple analysts cut price targets, including Baird to $117 from $125, Stifel to $100 from $110, and JPMorgan to $90 from $96. Full-year 2026 guidance midpoint of $2.83B came in roughly 5% below Street estimates.
May 19Revvity raised 2026 outlook to $2.81-2.84B revenue and announced China Immunodiagnostics divestiture, but analysts cut PTs (Baird $117, Stifel $100, JPM $90) after FY guide came in below consensus.Mixed▶
Revvity reported Q1 2026 results on May 5, with revenue up 7% to $711M (vs. $704M FactSet consensus) and non-GAAP EPS of $1.06, beating the $1.02-1.04 estimate. Operating margin expanded to 23.6%, above its 23% prior expectation. The company plans to divest its China Immunodiagnostics business, which represented roughly 6% of 2025 revenue, with a close expected by end of 2027. FY26 pro-forma guidance was set to $2.81-2.84B in revenue with adjusted EPS of $5.20-5.30, which came in about 5% below Street estimates and prompted multiple analyst price-target cuts. The FDA also cleared Revvity's Total Testosterone ChLIA automated immunoassay in May 2026. Management presented at the BofA Global Healthcare Conference on May 13.
May 18T. Rowe Price disclosed a 9.0% passive stake (10.1 million shares) in Revvity via a Schedule 13G/A filing on May 15, 2026.Positive▶
T. Rowe Price disclosed beneficial ownership of 10.1 million Revvity shares (9.0%) in an amended Schedule 13G/A filed on May 15, 2026. Revvity presented at the Bank of America Global Healthcare Conference on May 13, 2026, following Q1 results on May 5 that beat EPS expectations at $1.06 versus $1.04 consensus, with revenue up 9.3% YoY to $686.9 million. Management announced a planned divestiture of its China immunodiagnostics business (6% of 2025 revenue) expected to close by end of 2027 to streamline operations. Full-year 2026 guidance was updated on a pro forma basis to $2.81B-$2.84B revenue and $5.20-$5.30 adjusted EPS, with the midpoint coming in 5.2% below consensus. The company launched Opera Phenix OptIQ high-content screening system and Signals BioDesign biologics software.
May 15Revvity Q1 sales up 9.3% to $686.9M beats estimates; three analysts cut PTs as China immunodiagnostics divestiture planned.Mixed▶
Revvity reported Q1 2026 results on May 6, 2026 with sales of $686.9 million, up 9.3% YoY, and non-GAAP EPS of $1.06 (4.5% above consensus). Full-year revenue guidance of $2.83 billion midpoint came in 5.2% below analyst estimates. FY26 EPS guidance set at $5.20-$5.30. The company secured FDA clearance for a new testosterone testing solution and announced plans to divest its immunodiagnostics business in China to enhance growth rates and margins. Stock trades at $97.76, up from $86.51 just before earnings. Analyst PT cuts as of May 15: Baird $125 to $117, Stifel $110 to $100, JPMorgan $96 to $90.
May 14Revvity beat Q1 2026 with adj EPS $1.06 but divests China immunodiagnostics as analysts cut targetsMixed▶
Revvity reported Q1 2026 results on May 5, 2026 with revenue of $711M (up from $665M YoY) and adjusted EPS of $1.06 beating the $1.02 consensus. The company announced a strategic decision to divest its immunodiagnostics business in China, representing a major portfolio optimization move. 2026 guidance projects total revenue of $2.81-$2.84B (4-5% growth, 3-4% organic) and adjusted EPS of $5.20-$5.30. Revvity presented at the Bank of America Global Healthcare Conference on May 13, 2026. Multiple analysts cut price targets post-earnings: Baird to $117 from $125, Stifel to $100 from $110, JPMorgan to $90 from $96, while Barclays raised to $105 from $95 and TD Cowen raised to $120 from $115. Revvity also secured FDA clearance for a new testosterone testing solution and announced an Eli Lilly TuneLab collaboration. Mixed sentiment as China exit and downward revenue guide weigh on outlook.
May 13Revvity is set to present at the BofA Securities 2026 Health Care Conference on May 13, 2026, following its Q1 beat and confirmation of plans to divest its China immunodiagnostics business.Positive▶
Revvity will present at the BofA Securities 2026 Health Care Conference on Wednesday, May 13, 2026 at 9:20 a.m. PT, providing a near-term catalyst for management commentary on its updated 2026 outlook. The company reported Q1 2026 revenue of $711.1 million (+7% YoY) and adjusted EPS of $1.06, beating consensus of $1.02. Revvity reaffirmed pro forma 2026 guidance of $2.81-$2.84 billion revenue and adjusted EPS of $5.20-$5.30, while signaling its planned divestiture of the China immunodiagnostics business (about 4.5% of expected 2026 revenue) to focus on higher-return areas. Additionally, Rep. Gilbert Ray Cisneros, Jr. disclosed an acquisition of RVTY stock on May 12, 2026, a notable Congressional trading signal. Risk includes execution of portfolio pruning and margin pressure from the China exit.
May 12Rep. Gilbert Cisneros disclosed a Revvity stock purchase on May 12 as the company heads into the May 13 BofA Healthcare Conference presentation.Mixed▶
A May 12 disclosure showed Rep. Gilbert Ray Cisneros, Jr. acquired Revvity shares, a modest political-insider signal flagged by trackers. The disclosure lands one day before Revvity's BofA Securities 2026 Healthcare Conference presentation on May 13 at 9:20am PT. Context: Revvity's May 5 Q1 print beat with revenue of $711M and adjusted EPS of $1.06, but full-year revenue guidance of $2.81-2.84B came in ~5% below consensus due to the planned China immunodiagnostics divestiture. Bear case: management cut FY revenue and the China exit removes ~4.5% of expected 2026 revenue.
May 11Revvity beat Q1 2026 EPS and announced China Immunodiagnostics divestiture; Barclays raised PT to $105 from $95.Mixed▶
Revvity reported Q1 2026 results on May 5 with EPS of $1.06 beating $1.04 estimates and revenue of $711M beating $705M consensus, with sales rising 9.3% YoY. The company announced plans to divest its China Immunodiagnostics business, which is expected to deliver a 100 bps improvement in annual organic growth and 30 bps lift in operating margins. Revvity reset 2026 guidance to $2.81-$2.84B revenue (4-5% growth) and adjusted EPS of $5.20-$5.30, with full-year revenue guidance coming in 5.2% below prior estimates. The company launched the Opera Phenix OptIQ system, introduced Xynthetica AI-as-a-service, and announced BioDesign cloud-native molecular design. A bylaw change was adopted allowing 25% shareholders to call special meetings. Barclays maintained Equal-Weight and raised PT to $105 from $95 on May 7.
May 8Beats Q1 2026 with $711.1M revenue and $1.06 adjusted EPS; lowers FY26 on China divestitureMixed▶
Revvity reported Q1 2026 revenue of $711.1M (beat $704.67M estimate) and adjusted EPS of $1.06 (beat $1.02 estimate), with shares up 2.7% to $88.8 premarket. Company lowering 2026 adjusted profit guidance to $5.20-$5.30 per share. Key driver: divestiture of China Immunodiagnostics unit (6% of revenues) to refocus on core life sciences; expected to improve organic growth 100 bps and operating margins 30 bps. Launched AI-enabled software (BioDesign, Xynthetica) for drug discovery. Multiple analysts cut targets: Baird to $117, Stifel to $100, JPMorgan to $90.
May 7Revvity beats Q1 but lowers full-year guidance; plans China business divestitureMixed▶
Revvity reported Q1 2026 EPS of $1.06, topping consensus of $1.02, with 7% YoY revenue growth. However, the company lowered FY2026 guidance to EPS of $5.20-5.30 (vs. $5.40 consensus) and revenue of $2.8B (vs. $3.0B consensus). The company plans to divest its China Immunodiagnostics business (~6% of revenue) by 2027, with definitive agreement expected in Q2 2026. Multiple analysts cut price targets including Stifel, Baird, and JPMorgan.
May 6Revvity Reports Q1 2026 EPS Beat but Revises FY 2026 Guidance LowerNeutral▶
Revvity reported Q1 2026 earnings with adjusted EPS of $1.06, surpassing consensus estimate of $1.04, with revenue of $711M slightly below expected $719.2M. Stock jumped 7.3% on earnings beat despite revenue miss, with organic growth and adjusted EPS exceeding internal expectations. The company announced divestiture of its China immunodiagnostics business, approximately 6% of fiscal 2025 revenue, citing persistent policy-induced headwinds and pricing pressures. FY 2026 guidance revised to EPS of $5.20-5.30 vs. consensus $5.40, and revenue of $2.8B vs. consensus $3.0B.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| RVTYREVVITY | $101.11 | +6.01% | -0.1% | 16.4x | 1.05 | $10.6B |
| ISRGINTUITIVE | $416.51 | -5.30% | -0.0% | 37.3x | 1.51 | $155.8B |
| ABTABBOTT | $88.21 | +0.50% | -0.2% | 14.5x | 0.65 | $152.9B |
| SYKSTRYKER | $310.30 | -1.02% | +0.1% | 18.8x | 0.81 | $120.2B |
| MDTMEDTRONIC | $80.25 | +2.69% | +1.1% | 12.9x | 0.63 | $100.3B |
| BSXBOSTON | $47.37 | -17.11% | +2.2% | 15.2x | 0.62 | $84.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.